Myomo (MYO) to Announce Earnings on Wednesday

Myomo (NYSEAMERICAN:MYO) is expected to post its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Myomo to post earnings of ($0.10) per share and revenue of $10.3520 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Myomo Stock Up 6.2%

MYO traded up $0.07 on Tuesday, hitting $1.10. The company had a trading volume of 100,432 shares, compared to its average volume of 572,033. The company has a debt-to-equity ratio of 1.21, a current ratio of 2.73 and a quick ratio of 2.36. Myomo has a 52-week low of $0.60 and a 52-week high of $2.02. The stock has a fifty day simple moving average of $1.13 and a 200-day simple moving average of $0.92. The firm has a market capitalization of $42.70 million, a P/E ratio of -3.08 and a beta of 1.50.

Insider Buying and Selling at Myomo

In other news, Director Thomas F. Kirk purchased 43,401 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The shares were bought at an average price of $0.91 per share, for a total transaction of $39,494.91. Following the purchase, the director directly owned 628,863 shares in the company, valued at approximately $572,265.33. This trade represents a 7.41% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Joseph M. Jr. Manko acquired 170,830 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The shares were purchased at an average cost of $0.86 per share, for a total transaction of $146,913.80. Following the completion of the transaction, the director directly owned 2,279,408 shares in the company, valued at $1,960,290.88. The trade was a 8.10% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought 341,205 shares of company stock valued at $317,748 over the last 90 days. Corporate insiders own 12.14% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. LPL Financial LLC boosted its stake in Myomo by 132.9% during the 4th quarter. LPL Financial LLC now owns 177,000 shares of the company’s stock valued at $161,000 after purchasing an additional 101,000 shares during the last quarter. Lazard Asset Management LLC purchased a new position in shares of Myomo in the second quarter worth $98,000. Jump Financial LLC raised its stake in shares of Myomo by 42.2% in the second quarter. Jump Financial LLC now owns 87,000 shares of the company’s stock worth $188,000 after purchasing an additional 25,802 shares during the last quarter. New York State Common Retirement Fund bought a new position in shares of Myomo during the second quarter valued at $97,000. Finally, XTX Topco Ltd bought a new position in shares of Myomo during the second quarter valued at $134,000. 44.99% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets upped their target price on Myomo from $9.50 to $10.00 and gave the stock a “buy” rating in a report on Monday, June 8th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $7.50.

Myomo Company Profile

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.